1. BRAF-mutated histiocytosis of the skull lacking the expression of Langerhans cell markers
- Author
-
Gwenaël Lorillon, Jean-François Emile, Marc Polivka, Homa Addle-Biassette, Emmanuel Mandonnet, and Franck-Neil El Sissy
- Subjects
Pathology ,medicine.medical_specialty ,Langerhans cell ,business.industry ,Histology ,General Medicine ,medicine.disease ,Pathology and Forensic Medicine ,Lesion ,Histiocytosis ,Skull ,medicine.anatomical_structure ,Neurology ,Langerhans cell histiocytosis ,Immunochemistry ,medicine ,Neurology (clinical) ,medicine.symptom ,business ,Histiocyte - Abstract
Langerhans cell histiocytosis (LCH) is a rare condition affecting children more frequently than adults. LCH can involve any organ in the body and has a wide spectrum of clinical presentation from a single self-healing bone lesion to a multisystemic life-threatening disease. The diagnosis of LCH requires histology with compatible clinical and radiological findings. Positive immunochemistry for both CD1a and CD207 is required for a definitive diagnosis of LCH. The majority of LCH shares oncogenic BRAFV600E mutation. We report the case of a 55-year-old adult who presented with a single lytic self-healing lesion of the skull, invading adjacent soft tissues. The histology and cytology were also typical of LCH, and tumor cells contained the BRAFV600E mutation. However, histiocytes were negative for CD1a and CD207. We suggest that this case might be considered as LCH, despite its abnormal phenotype. .
- Published
- 2020